Psychiatric NP Scope of Practice for Anxiety in North Carolina

If you’re a psychiatrist or PMHNP treating anxiety disorders via telehealth, you already know the clinical side: matching the right medication to the right patient, titrating doses, monitoring response. But there’s another layer that keeps many providers up at night — navigating the patchwork of federal and state prescribing laws that govern how you can legally treat anxiety patients remotely.

Here’s the reality: telehealth prescribing for anxiety has never been more accessible, thanks to COVID-era flexibilities that the DEA extended through December 31, 2025. But those rules could change. And even with federal flexibility, every state has its own telehealth laws, controlled substance requirements, and scope-of-practice rules that determine exactly what you can and cannot do when treating anxiety via video visit.

This guide breaks down what providers actually need to know — from DEA regulations on benzodiazepines to state-by-state differences in PMHNP prescribing authority — so you can practice confidently, stay compliant, and focus on patient care rather than regulatory anxiety.

Federal Rules: What the DEA Says About Prescribing Anxiety Meds via Telehealth

Let’s start with the elephant in the room: benzodiazepines. Many effective anxiety treatments — SSRIs, SNRIs, buspirone, hydroxyzine — aren’t controlled substances, so federal law doesn’t restrict them beyond standard medical practice. But benzos like alprazolam (Xanax), clonazepam (Klonopin), and lorazepam (Ativan) are Schedule IV controlled substances, and that’s where the Ryan Haight Act comes in.

The Ryan Haight Act: The Baseline Rule

Under federal law (21 U.S.C. §829(e)), prescribing controlled substances ‘by means of the Internet’ typically requires an in-person medical evaluation before the first prescription. This was designed to prevent online pill mills but created a major barrier for legitimate telehealth psychiatric care.

Exceptions exist when the provider is engaged in the ‘practice of telemedicine’ — such as during a public health emergency, when the patient is located in a DEA-registered facility during the visit, or if the prescriber has a special telemedicine DEA registration (which DEA still hasn’t fully implemented as of 2026).

COVID-Era Flexibilities: Still in Effect Through 2025

Since March 2020, the DEA has allowed controlled substance prescribing via telehealth without a prior in-person exam under public health emergency waivers. Most recently, in November 2024, the DEA announced a third extension through December 31, 2025, maintaining access to remote prescribing for medications including benzodiazepines.

What this means for anxiety providers:

• You can initiate benzodiazepine treatment after a telehealth evaluation (video visit) without ever seeing the patient in person
• This applies to Schedule II–V controlled substances, including stimulants for comorbid ADHD
• The evaluation must meet standard-of-care requirements — thorough history, mental status exam, appropriate documentation
• You still need your DEA registration and must comply with all state laws

The catch: This is temporary policy. The DEA proposed new rules in early 2023 that would have reinstated in-person requirements (with limited 30-day telehealth allowances), but after receiving over 38,000 public comments — many from mental health providers — they postponed implementation and are reconsidering a ‘new path forward.’

Bottom line: As of February 2026, federal law still permits fully remote prescribing of anxiety medications including benzodiazepines. But prepare for potential changes — the DEA could introduce new requirements at any time, possibly including hybrid models (initial telehealth visit allowed, but in-person exam required within a certain timeframe for continuation).

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where Telehealth Gets Complicated

Federal DEA rules set the floor, but states add layers of requirements that vary significantly. Here’s what matters for the six largest telehealth markets:

California: Telehealth-Friendly with One Big Catch

Licensing: You must hold a California medical license. CA is not in the Interstate Medical Licensure Compact (IMLC), so out-of-state providers need to go through the full state licensing process.

Telehealth Rules: California doesn’t require an in-person exam before prescribing via telehealth. As long as the ‘appropriate prior examination’ meets standard of care — which can be done via video or even asynchronous methods if clinically adequate — you’re good to prescribe.

Controlled Substances: No state restrictions beyond federal law. You can prescribe benzodiazepines via telehealth just like you would in person.

PDMP: You must check California’s CURES database for Schedule II–IV drugs at least every 4 months for ongoing therapy.

E-Prescribing: Mandatory for all prescriptions since 2022.

PMHNP Scope: California is transitioning to full nurse practitioner independence under AB 890. As of 2023, experienced NPs can practice independently in certain settings; by January 2026, qualified NPs can apply for full independence across all settings. This means PMHNPs in California will soon be able to evaluate and treat anxiety patients — including prescribing benzodiazepines — without physician oversight.

Texas: Video Required, NP Restrictions Apply

Licensing: Texas is in the IMLC, making multi-state licensing easier for psychiatrists.

Telehealth Rules: Texas requires synchronous audio-visual interaction (live video) to establish a new patient relationship via telehealth. Phone-only won’t cut it for initial evaluations.

Controlled Substances: Teleprescribing is permitted for mental health conditions. However, Texas prohibits using telemedicine to prescribe Schedule II controlled substances for chronic pain management (not relevant to anxiety treatment, but worth noting).

PDMP: Texas mandates checking the state Prescription Monitoring Program before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol.

NP Prescribing: Here’s where Texas gets restrictive. APRNs cannot prescribe Schedule II controlled substances in outpatient settings except in hospitals or hospice care. For psychiatric care, this mainly affects ADHD stimulants when treating comorbid conditions. PMHNPs in Texas operate under a Prescriptive Authority Agreement with a physician and can prescribe Schedule III–IV medications (including benzos) but not Schedule II outside of inpatient settings.

Florida: Psychiatric Carve-Outs and Out-of-State Options

Licensing: Florida offers a unique Telehealth Provider Registration for out-of-state clinicians, allowing practice without a full Florida license (subject to eligibility requirements and fingerprinting).

Telehealth Rules: Florida requires written informed consent for telehealth treatment. Document this in the patient’s chart.

Controlled Substances: Florida explicitly prohibits prescribing Schedule II controlled substances via telehealth except for four scenarios, one of which is treatment of psychiatric disorders. This means psychiatrists and psychiatric NPs can prescribe stimulants or other Schedule II medications for mental health conditions via telehealth, but other providers cannot prescribe them for non-psychiatric uses.

PDMP: Florida requires checking E-FORCSE before prescribing any Schedule II–V controlled substance and at least every 90 days for ongoing therapy.

NP Prescribing: Florida PMHNPs must work under a physician supervisory protocol. However, there’s a special provision: while Florida NPs are generally limited to 7-day supplies of Schedule II, that limit does not apply to psychiatric nurses (PMHNPs with specific certification) when treating mental illness. This gives psychiatric specialists more flexibility than general practice NPs.

New York: Full Independence for Experienced NPs, Strict PDMP Rules

Licensing: New York is not in the IMLC. Out-of-state psychiatrists must obtain a full NY license.

Telehealth Rules: No state-mandated in-person exam. Telehealth (including audio-only for some mental health services) is permitted as long as it meets standard of care.

Controlled Substances: No state restrictions beyond federal law. New York providers have been prescribing benzodiazepines via telehealth widely since COVID.

PDMP: New York’s I-STOP law requires prescribers to check the state Prescription Monitoring Program before every Schedule II, III, or IV prescription. This is one of the strictest PDMP requirements in the country — you must query the database each time you prescribe a benzodiazepine, not just initially.

E-Prescribing: Mandatory for all medications since 2016 (New York was the first state to require this).

NP Independence: New York enacted full practice authority for experienced NPs in 2022. After completing 3,600 hours of practice under a physician collaboration, PMHNPs can practice independently — including prescribing controlled substances without physician oversight.

Pennsylvania: PDMP Checks Every Time for Benzos

Licensing: Pennsylvania is in the IMLC, facilitating multi-state physician licensing.

Telehealth Rules: No comprehensive statute detailing teleprescribing, but state boards permit telemedicine as long as it meets in-person standards. Real-time audio-visual is recommended for initial evaluations.

Controlled Substances: Follows federal law — no state-specific telehealth prescribing ban.

PDMP: Pennsylvania requires checking the state PDMP before the initial prescription of any opioid or benzodiazepine and for each subsequent prescription. This means every time you refill a patient’s Xanax, you’re required to query the database — not just every 30 or 90 days, but every single prescription.

NP Prescribing: Pennsylvania PMHNPs must operate under a collaborative agreement with a physician. NPs can prescribe:

• Schedule II: up to 30-day supply (with physician notification within 24 hours)
• Schedule III–IV (including benzos): up to 90-day supply

The collaborative agreement must explicitly authorize controlled substance prescribing.

Illinois: Full Practice Authority Available for Experienced NPs

Licensing: Illinois is in the IMLC for physicians and joined the Nurse Licensure Compact for RNs in 2022.

Telehealth Rules: Illinois permits telehealth without requiring an in-person exam. The state even explicitly allows audio-only telehealth for mental health services when video isn’t available (though providers should use video when possible for thorough evaluations).

Controlled Substances: No state restrictions on teleprescribing beyond federal law.

PDMP: Required to consult the Illinois Prescription Monitoring Program for all Schedule II prescriptions; strongly encouraged for benzodiazepines.

NP Independence: Illinois offers Full Practice Authority (FPA) for APRNs who have completed 4,000 hours of clinical experience and additional training. FPA allows independent practice including prescribing, with one caveat: NPs prescribing Schedule II narcotics (opioids) in the first 5 years of FPA must have a physician consultation relationship available. For non-narcotic Schedule II (stimulants) or Schedule III–V (benzos), fully independent NPs can prescribe without physician input.

Additional Requirement: Illinois prescribers must have a state controlled substance license in addition to their DEA registration.

Psychiatrists vs PMHNPs: Scope of Practice Differences That Matter

Psychiatrists: Full Authority, No Supervision

If you’re a psychiatrist (MD/DO), your scope is straightforward: you have full independent practice authority in every state. You can:

• Diagnose any anxiety disorder
• Prescribe any medication (controlled or non-controlled) within accepted medical practice
• Provide psychotherapy (though many focus on medication management)
• Practice via telehealth anywhere you’re licensed

No state requires psychiatrists to work under supervision or obtain collaborative agreements. Your main compliance tasks are:

• Maintaining state licensure in each state where your patients are located
• Following DEA controlled substance regulations
• Complying with state-specific PDMP requirements
• Using e-prescribing where mandated
• Documenting telehealth encounters thoroughly

PMHNPs: Variable Authority Based on State

Psychiatric Mental Health Nurse Practitioners can diagnose and treat anxiety in all states, but the regulatory landscape varies significantly:

Full Practice States (experienced NPs can practice independently):

• New York: After 3,600 hours
• Illinois: After 4,000 hours (Full Practice Authority)
• California: By 2026 for qualified NPs

Restricted Practice States (physician collaboration required):

• Texas: Prescriptive Authority Agreement required; cannot prescribe Schedule II outpatient
• Florida: Supervisory protocol required; 7-day Schedule II limit (except psych NPs treating mental health)
• Pennsylvania: Collaborative agreement required; 30-day Schedule II limit, 90-day Schedule III–IV limit

Why this matters for telehealth platforms: Klarity and similar services must ensure PMHNPs have appropriate physician collaborations in place in restrictive states. In full-practice states, experienced NPs can operate entirely independently, simplifying deployment.

The Economics of Patient Acquisition: Why Platform Models Make Sense

Let’s talk about the elephant in the room: acquiring anxiety patients is expensive and time-consuming.

The DIY marketing reality:

• Google Ads for mental health keywords cost $15–40+ per click. Most clicks don’t convert. A realistic cost per booked patient through PPC is $200–400+, and that’s after months of testing and optimization
• SEO takes 6–12 months of consistent investment before generating meaningful patient flow. You need technical expertise, content creation, and patience most solo providers don’t have
• Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of providers. Zocdoc charges per booking ($35–100+) but total monthly costs add up
• Total monthly spend: Most providers trying to build a telehealth practice through DIY marketing invest $3,000–5,000/month with uncertain results

When you factor in ALL costs — agency fees, ad spend, staff time qualifying leads, no-show rates from cold leads, and failed campaigns — acquiring a qualified psychiatric patient typically costs $200–500+.

Klarity’s platform model removes that risk entirely:

• Pay-per-appointment: You only pay a standard listing fee when a qualified patient books with you
• Pre-qualified patients: Matched to your specialty and availability before they reach you
• No upfront marketing spend: No monthly subscriptions, no wasted ad budget
• Built-in infrastructure: Telehealth platform, e-prescribing, credentialing support included
• Both insurance and cash-pay patients: Multiple revenue streams without separate marketing

The business case is simple: Instead of gambling $3,000–5,000/month on marketing that might not work, you pay only when you see patients. That’s guaranteed ROI.

For providers who want to focus on clinical care rather than becoming marketing experts, a platform that handles patient acquisition is the smart economic choice — especially when you’re starting out or scaling across multiple states.

Compliance Checklist: What You Need to Practice Anxiety Telehealth Legally

Before you see your first telehealth anxiety patient:

☑ State medical/nursing license in the state where the patient is located☑ DEA registration in your state of practice (required for controlled substances)☑ State controlled substance license if required (Illinois, Florida, etc.)☑ PDMP registration in each state where you’ll prescribe controlled medications☑ E-prescribing system with DEA-compliant EPCS (two-factor authentication for controlled substances)☑ Malpractice insurance that covers telehealth☑ Collaborative agreement (if you’re a PMHNP in a restricted state)☑ Telehealth consent documentation process (especially in Florida and Illinois)

For each anxiety patient encounter:

☑ Conduct standard-of-care evaluation via telehealth (preferably video)☑ Check state PDMP before prescribing controlled substances (timing varies by state — some require every prescription, others quarterly)☑ Document telehealth-specific elements (patient location, technology used, consent obtained)☑ Use e-prescribing for all medications (mandatory in most states)☑ Follow DEA regulations for controlled substance prescribing (legitimate medical purpose, usual course of practice)☑ Maintain appropriate follow-up schedules (especially for benzodiazepine management)

What’s Coming: Preparing for Post-2025 DEA Rules

The current federal telehealth flexibility for controlled substances expires December 31, 2025. The DEA is working on permanent regulations but hasn’t released them yet.

Possible scenarios:

1. Extension of current flexibilities (most hopeful)
2. Hybrid model — initial telehealth visit allowed, but in-person exam required within 30–90 days to continue prescribing
3. Special Telehealth Registration — DEA finally implements the registration process outlined in the Ryan Haight Act, allowing qualified providers to prescribe controlled substances online
4. Return to pre-COVID rules — in-person exam required before any controlled substance prescription (least likely given pushback)

How to prepare:

• Monitor DEA announcements and professional association updates
• Consider establishing affiliate clinic relationships where patients could have in-person exams if needed
• Document your telehealth encounters thoroughly to demonstrate standard-of-care compliance
• Be ready to adapt your practice model if regulations change

Most experts believe the DEA will maintain some level of telehealth flexibility given the massive expansion of access to mental health care, but the details matter.

The Bottom Line: Compliance Doesn’t Have to Be Overwhelming

Yes, navigating telehealth prescribing laws for anxiety treatment involves multiple layers of regulation — federal DEA rules, state telehealth statutes, PDMP requirements, scope-of-practice limitations, and e-prescribing mandates.

But here’s the reality: thousands of psychiatrists and PMHNPs are successfully treating anxiety patients via telehealth right now, staying compliant while delivering excellent care.

The key is:

1. Know your federal baseline (DEA rules on controlled substances)
2. Understand your state’s specific requirements (licensing, PDMP, telehealth statutes)
3. Work with platforms or systems that handle the infrastructure (e-prescribing, credentialing, patient acquisition)
4. Document thoroughly and follow standard-of-care principles
5. Stay updated on regulatory changes

If you’re looking to expand your anxiety treatment practice via telehealth without the headache of DIY patient acquisition and compliance management, platforms like Klarity Health handle the heavy lifting — patient matching, credentialing support, built-in telehealth infrastructure — so you can focus on what you do best: helping patients overcome anxiety.

Ready to explore telehealth opportunities? Understanding these regulations is the first step. The second is finding a model that makes compliance straightforward and patient acquisition predictable.

FAQ: Telehealth Prescribing for Anxiety Treatment

Can I prescribe benzodiazepines via telehealth without ever seeing the patient in person?

Yes, under current federal rules (extended through December 31, 2025), you can prescribe Schedule II–V controlled substances including benzodiazepines after a telehealth evaluation, without a prior in-person exam. You must conduct a thorough video evaluation that meets standard of care and comply with all state requirements (PDMP checks, e-prescribing, etc.). These federal flexibilities may change in 2026, so monitor DEA announcements.

Do I need a separate license in each state where my telehealth patients are located?

Yes. You must hold a valid medical or nursing license in every state where your patients are physically located during the telehealth encounter. Some states participate in licensure compacts (IMLC for physicians, NLC for RNs) that can streamline the process, but you still need authorization in each state. Florida offers a unique Telehealth Provider Registration for out-of-state clinicians as an alternative to full licensure.

What’s the difference between PDMP requirements in different states?

PDMP (Prescription Drug Monitoring Program) check requirements vary significantly. Pennsylvania requires checking before every benzodiazepine prescription. New York requires checking before every Schedule II–IV prescription. California requires checking at least every 4 months for ongoing therapy. Texas requires checking before prescribing opioids, benzos, barbiturates, or carisoprodol. Always check your specific state’s requirements and integrate PDMP queries into your workflow.

Can PMHNPs prescribe anxiety medications independently, or do they need physician oversight?

It depends on the state. New York and Illinois allow experienced PMHNPs (after 3,600 and 4,000 hours respectively) to practice independently, including prescribing controlled substances. California is transitioning to full independence by 2026. Texas, Florida, and Pennsylvania require PMHNPs to work under physician collaborative agreements or supervisory protocols. Some states also restrict what Schedule medications NPs can prescribe.

Is audio-only (phone) telehealth acceptable for prescribing anxiety medications?

Generally, video is strongly recommended for initial evaluations. Some states like Illinois explicitly allow audio-only for mental health services when video isn’t available. However, federal DEA regulations under the Ryan Haight Act (which will eventually replace current COVID waivers) typically require interactive audio-visual for controlled substance prescribing. Phone-only should be reserved for follow-ups with established patients or situations where video truly isn’t feasible, and you should document why video wasn’t used.

What happens if DEA telehealth rules change after 2025?

The current flexibilities expire December 31, 2025, but DEA is working on permanent regulations. Possible outcomes include continued flexibility, hybrid models requiring eventual in-person exams, or a special telehealth DEA registration process. Monitor DEA announcements and professional association guidance. If you’re working with a telehealth platform like Klarity, they’ll help you navigate regulatory changes and maintain compliance.

Are there restrictions on prescribing certain anxiety medications via telehealth?

Non-controlled anxiety medications (SSRIs, SNRIs, buspirone, hydroxyzine) have no special telehealth restrictions — prescribe them as you would in person. Controlled substances (primarily benzodiazepines for anxiety) follow federal DEA rules and state-specific requirements. Some states have unique provisions: Florida permits Schedule II prescribing via telehealth for psychiatric conditions but bans it for other uses; Texas prohibits Schedule II prescribing for chronic pain via telehealth; Texas NPs cannot prescribe Schedule II outpatient at all. Always verify both federal and your specific state’s rules.

How do e-prescribing requirements work for controlled anxiety medications?

Most states now mandate e-prescribing for controlled substances. California and New York require e-prescribing for all medications. You’ll need an EPCS-certified e-prescribing system with two-factor authentication (typically a token or biometric). Paper prescriptions for controlled substances are being phased out in most states. Telehealth platforms typically provide integrated e-prescribing systems that meet these requirements.

Sources & References

1. DEA & HHS Telemedicine Extension Announcement – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ – November 15, 2024 – https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. 21 U.S.C. § 829(e) – Ryan Haight Act (Federal controlled-substance prescribing requirements) – Current through 2025 – https://www.law.cornell.edu/uscode/text/21/829

3. Center for Connected Health Policy – ‘State Telehealth Policies for Online Prescribing’ – Updated January 9, 2026 – https://www.cchpca.org/topic/online-prescribing/

4. Florida Statutes § 456.47 (Telehealth Services) – 2025 edition – http://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

5. Florida Statutes § 464.012 (APRN controlled substance prescribing) – 2025 edition – http://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0464/Sections/0464.012.html

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94